1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Seizures - Pipeline Review, H1 2016

Seizures - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 201 pages

Seizures - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Seizures - Pipeline Review, H1 2016’, provides an overview of the Seizures pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seizures and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Seizures
- The report reviews pipeline therapeutics for Seizures by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Seizures therapeutics and enlists all their major and minor projects
- The report assesses Seizures therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Seizures

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Seizures
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Seizures - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Seizures Overview 8
Therapeutics Development 9
Pipeline Products for Seizures - Overview 9
Pipeline Products for Seizures - Comparative Analysis 10
Seizures - Therapeutics under Development by Companies 11
Seizures - Therapeutics under Investigation by Universities/Institutes 14
Seizures - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Seizures - Products under Development by Companies 19
Seizures - Products under Investigation by Universities/Institutes 23
Seizures - Companies Involved in Therapeutics Development 24
Adamas Pharmaceuticals, Inc. 24
Advicenne Pharma 25
Alexza Pharmaceuticals, Inc. 26
Biscayne Pharmaceuticals, Inc. 27
Catalyst Pharmaceutical Partners, Inc. 28
Eisai Co., Ltd. 29
GW Pharmaceuticals Plc 30
INSYS Therapeutics, Inc. 31
Marinus Pharmaceuticals, Inc. 32
Novartis AG 33
OPKO Health, Inc. 34
Pfizer Inc. 35
PTC Therapeutics, Inc. 36
RODES Inc. 37
Sage Therapeutics, Inc. 38
SciFluor Life Sciences, LLC 39
SK Biopharmaceuticals Co., Ltd. 40
Turing Pharmaceuticals AG 41
UCB S.A. 42
Ultragenyx Pharmaceutical Inc. 43
Upsher-Smith Laboratories, Inc. 44
Xenon Pharmaceuticals Inc. 45
XERIS Pharmaceuticals, Inc. 46
Zogenix, Inc. 47
Seizures - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Target 49
Assessment by Mechanism of Action 52
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
ADS-4101 - Drug Profile 58
ADV-6208 - Drug Profile 59
ADV-6770 - Drug Profile 60
alprazolam - Drug Profile 61
AMPX-0079 - Drug Profile 63
ataluren - Drug Profile 64
BIS-001 - Drug Profile 68
brivaracetam - Drug Profile 69
Cannabidiol - Drug Profile 72
CCG-63802 - Drug Profile 74
CHEC-9 - Drug Profile 75
clobazam - Drug Profile 77
CPP-115 - Drug Profile 78
CUR-1916 - Drug Profile 80
diazepam - Drug Profile 81
diazepam - Drug Profile 82
Epidiolex - Drug Profile 83
everolimus - Drug Profile 86
fenfluramine hydrochloride - Drug Profile 92
fosphenytoin sodium - Drug Profile 93
ganaxolone - Drug Profile 94
lacosamide - Drug Profile 96
levetiracetam - Drug Profile 102
lorazepam - Drug Profile 105
magnesium valproate hydrate - Drug Profile 106
MB-003 - Drug Profile 107
midazolam hydrochloride - Drug Profile 108
Oligonucleotide for Dravet Syndrome - Drug Profile 109
perampanel - Drug Profile 110
pregabalin - Drug Profile 113
SAGE-217 - Drug Profile 115
SAGE-689 - Drug Profile 116
selurampanel - Drug Profile 117
sepranolone - Drug Profile 118
SF-0034 - Drug Profile 121
Small Molecule for Stroke and Epilepsy - Drug Profile 122
Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile 123
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 124
Small Molecules for Seizures - Drug Profile 125
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 126
TG-4155 - Drug Profile 128
TRP-001 - Drug Profile 129
TUR-004 - Drug Profile 130
TUR-005 - Drug Profile 131
UX-007 - Drug Profile 132
YKP-3089 - Drug Profile 134
Seizures - Recent Pipeline Updates 136
Seizures - Dormant Projects 188
Seizures - Discontinued Products 191
Seizures - Product Development Milestones 192
Featured News and Press Releases 192
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 197
Disclaimer 198

List of Tables
Number of Products under Development for Seizures, H1 2016 12
Number of Products under Development for Seizures - Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Comparative Analysis by Unknown Stage Development, H1 2016 21
Products under Development by Companies, H1 2016 22
Products under Development by Companies, H1 2016 (Contd..1) 23
Products under Development by Companies, H1 2016 (Contd..2) 24
Products under Development by Companies, H1 2016 (Contd..3) 25
Products under Investigation by Universities/Institutes, H1 2016 26
Seizures - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 27
Seizures - Pipeline by Advicenne Pharma, H1 2016 28
Seizures - Pipeline by Alexza Pharmaceuticals, Inc., H1 2016 29
Seizures - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016 30
Seizures - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 31
Seizures - Pipeline by Eisai Co., Ltd., H1 2016 32
Seizures - Pipeline by GW Pharmaceuticals Plc, H1 2016 33
Seizures - Pipeline by INSYS Therapeutics, Inc., H1 2016 34
Seizures - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016 35
Seizures - Pipeline by Novartis AG, H1 2016 36
Seizures - Pipeline by OPKO Health, Inc., H1 2016 37
Seizures - Pipeline by Pfizer Inc., H1 2016 38
Seizures - Pipeline by PTC Therapeutics, Inc., H1 2016 39
Seizures - Pipeline by RODES Inc., H1 2016 40
Seizures - Pipeline by Sage Therapeutics, Inc., H1 2016 41
Seizures - Pipeline by SciFluor Life Sciences, LLC, H1 2016 42
Seizures - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 43
Seizures - Pipeline by Turing Pharmaceuticals AG , H1 2016 44
Seizures - Pipeline by UCB S.A., H1 2016 45
Seizures - Pipeline by Ultragenyx Pharmaceutical Inc., H1 2016 46
Seizures - Pipeline by Upsher-Smith Laboratories, Inc., H1 2016 47
Seizures - Pipeline by Xenon Pharmaceuticals Inc., H1 2016 48
Seizures - Pipeline by XERIS Pharmaceuticals, Inc., H1 2016 49
Seizures - Pipeline by Zogenix, Inc., H1 2016 50
Assessment by Monotherapy Products, H1 2016 51
Number of Products by Stage and Target, H1 2016 53
Number of Products by Stage and Mechanism of Action, H1 2016 56
Number of Products by Stage and Route of Administration, H1 2016 58
Number of Products by Stage and Molecule Type, H1 2016 60
Seizures Therapeutics - Recent Pipeline Updates, H1 2016 139
Seizures - Dormant Projects, H1 2016 191
Seizures - Dormant Projects (Contd..1), H1 2016 192
Seizures - Dormant Projects (Contd..2), H1 2016 193
Seizures - Discontinued Products, H1 2016 194

List of Figures
Number of Products under Development for Seizures, H1 2016 12
Number of Products under Development for Seizures - Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Products, H1 2016 20
Assessment by Monotherapy Products, H1 2016 51
Number of Products by Top 10 Targets, H1 2016 52
Number of Products by Stage and Top 10 Targets, H1 2016 52
Number of Products by Top 10 Mechanism of Actions, H1 2016 55
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 55
Number of Products by Routes of Administration, H1 2016 57
Number of Products by Stage and Routes of Administration, H1 2016 57
Number of Products by Molecule Types, H1 2016 59
Number of Products by Stage and Molecule Types, H1 2016 59

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.